Anderson Dyaarl Lee Jr. sold $10K of SERA

Anderson Dyaarl Lee Jr. (Chief Commercial Officer) sold 4,739 shares of SERA PROGNOSTICS, INC. (SERA) at $2.01 on 2026-06-11.

Original reporting
SEC EDGAR · Anderson Dyaarl Lee Jr.
Published Jun 15, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
high confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the CCO, including share count, price, and post-transaction holdings; no company performance or guidance is mentioned.

02

Market read

Primarily useful for monitoring insider behavior; limited direct trading signal without additional fundamental catalysts.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the article provides no context beyond the trade details.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-15; sale dated 2026-06-11

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for SERA PROGNOSTICS, INC.

Company-level read

Ticker impact

$SERANeutralHigh confidence
Context

SEC Form 4 shows SERA’s Chief Commercial Officer sold 4,739 shares at $2.01 on 2026-06-11.

Expected impact

Likely minimal near-term impact; watch for follow-on insider activity or unusual volume.

Evidence & confidence

The filing is a standard Form 4 transaction with no stated 10b5-1 plan and no accompanying company-specific catalyst in the text.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be viewed as less “mechanical,” so traders may scrutinize whether more sales follow.

Key entities

  • SERA PROGNOSTICS, INC.

    Company whose insider transaction is disclosed on SEC Form 4.

  • Anderson Dyaarl Lee Jr.

    Chief Commercial Officer reporting an open-market sale of SERA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SERAMed

SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test • PreTRM® test volume increases 54% sequentially and approximately five-

$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t